Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TP03HN106

Phase 2Small molecule

TTalengen Institute of Life Sciences, Shenzhen, P.R. China.

TP03HN106 is one of 39 small molecule programs targeting Ischemia. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

38

Competitors

Pipeline

Status by Indication[3][1]

Indication

IschemiaActive, not recruiting

IschemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

159 competitors in Ischemia

#DrugCompanyPhaseTrials

Adenocard

Isordil

Cardizem

BBausch Health Americas, Inc.

Garamycin

SSchering-Plough

Flagyl

DDePuy Orthopaedics

Osmitrol

BB. Braun Medical Inc.

Procardia

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Avlosulfon

AAlmirall, S.A.

Remodulin

United Therapeutics

Remicade

OOrganon and Co

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemia1 trial

TP03HN106 in Patients With Critical Limb Ischemia

Recruiting·TTalengen Institute of Life Sciences, Shenzhen, P.R. China.·Phase 2·NCT06482892·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TP03HN106. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TP03HN106 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TP03HN106. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Talengen Institute of Life Sciences, Shenzhen, P.R. China. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTalengen Institute of Life Sciences, Shenzhen, P.R. China.

Related News